Neose Announces Presentation of GlycoPEGylated Factor VIIa Data at the American Society of Hematology Annual Meeting

HORSHAM, Pa.--(BUSINESS WIRE)--Dec 12, 2007 - Neose Technologies, Inc. (Nasdaq GM:NTEC) announced that two posters were presented regarding preclinical data for GlycoPEGylated recombinant Factor VIIa at the American Society of Hematology 49th Annual Meeting and Exposition in Altanta, Georgia. GlycoPEGylated Factor VIIa, currently in Phase I, is being developed by Novo Nordisk A/S under a license from Neose.

The posters are titled:

-- Platelet-Dependent Activity of GlycoPEGylated rFVIIa (co-authored by Novo Nordisk and Neose)

-- Activity and Regulation of Long-Acting Factor VIIa Analogs (co-authored by Novo Nordisk and The University of Texas Health Center)

The presentations are available on the Neose corporate website at: http://phx.corporate-ir.net/phoenix.zhtml?c=60494&p=irol-presentations

About Coagulation Factor VII

Factor VII/VIIa is used in the treatment of bleeding episodes and for the prevention of bleeding during surgery or invasive procedures in patients with congenital hemophilia with inhibitors to coagulation factors VIII or IX. The worldwide market for recombinant Factor VII was approximately $1 billion in 2006, with Novo Nordisk being the only participant.

About Neose Technologies, Inc.

Neose Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development of next-generation therapeutic proteins that are competitive with best-in-class protein drugs currently on the market, on its own and through strategic partnerships. The lead candidates in its pipeline, NE-180 for use in the treatment of chemotherapy-induced anemia and anemia associated with chronic kidney disease and GlycoPEG-GCSF for chemotherapy-induced neutropenia, target markets with aggregate sales in excess of $15 billion. For more information, please visit www.neose.com.

Neose "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: There are statements in this press release regarding our business that are "forward-looking statements" that involve risks and uncertainties. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statement, see the sections of Neose's Annual Report on Form 10-K for the year ended December 31, 2006, entitled "Risk Factors" and "Special Note Regarding Forward-Looking Statements" and discussions of potential risks and uncertainties in Neose's subsequent filings with the SEC.

Contact

Neose Technologies, Inc.
A. Brian Davis
Sr. Vice President and Chief Financial Officer
215-315-9000
or
Barbara Krauter
Manager, Corporate Communications
215-315-9004

Posted: December 2007

Comments